Sheet 1 of 1

U.S. Department of Commerce, Patent and Trademark Office					Atty Docket No.		Serial No.		
					PF-0185-2 CON		To Be As agne		
LIST OF REFERENCES CITED BY APPLICANTS					Applicant .2				
(Use several sheets if necessary)					Bandman et al.				
					Filing Date		Group	110	
					Herewith		To Be A	To Be Assigned	
U.S. Patent Documents									
*Examiner		Document					Filing		
Initial	 _	Number	Date	Name	Class	Subclass	If Appr	opriate	
<u></u>		<u> </u>			 			· · · · · · · · · · · · · · · · · · ·	
<u> </u>					 			 	
		<u> </u>			<u> </u>				
Foreign Patent Documents									
					}		Translation		
		Document	Date	Country	Class	Subclass	Yes	No	
					<u></u>			<u>[</u>	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
CA-	Carmeliet, P., et al., "Abnormal blood vessel development and lethality embryos lacking a single VEGF allele," <u>Nature</u> , 380:435-439 (1996)						ity in		
	2	Ferrara, N., et al., "Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene," <u>Nature</u> , 380:439-442 (1996)							
	3	Lee, J., et al., "Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4," Proc. Natl., Acad. Sci. USA, 93:1988-1992 (1996) (GI 1150989)							
	4	Aiello, L., et al., "Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and other Retinal Disorders," The New England Journal of Medicine, 331(22):1480-1487 (1994)							
	5	Aiello, L., et al., "Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins," Proc. Natl. Acad. Sci. USA. , 92:10457-10461 (1995)							
	6	Matzuk, M.M. Tem., Vol. 6, No. 4, 120-127 (1995)							
CA	7	Orlandini et al., PNAS:93:11675-11680 (1996)							
Examiner	0.	Saoud Date Considered 3/3/04							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.									